Welcome to our dedicated page for Citius Oncology SEC filings (Ticker: CTOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Citius Oncology, Inc. (Nasdaq: CTOR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an emerging growth company incorporated in Delaware and listed on Nasdaq, Citius Oncology reports material corporate events, governance decisions, and securities transactions through forms such as 8‑K, proxy statements, and registration-related documents.
Recent Form 8‑K filings describe events including amendments to the company’s 2024 Omnibus Stock Incentive Plan and unregistered sales of equity securities. For example, Citius Oncology has reported an increase in the number of shares of common stock authorized for issuance under the 2024 Omnibus Stock Incentive Plan and the issuance of warrants to a financial advisor in a private placement. Another 8‑K details stockholder voting results at the 2025 annual meeting, including the election of Class I directors, approval of the incentive plan amendment, and ratification of the independent registered public accounting firm.
The company’s definitive proxy statement on Schedule 14A outlines the agenda and voting procedures for the annual meeting, the proposals presented to stockholders, and information on the number of shares outstanding and entitled to vote. Regulation FD disclosures, such as the posting of an updated corporate presentation, are also reported via Form 8‑K and incorporated by reference.
Through Stock Titan, these filings are organized so that investors can quickly locate specific document types, such as current reports on material events, proxy materials, and other disclosures that complement Citius Oncology’s press releases about LYMPHIR™ (denileukin diftitox-cxdl) and its commercialization. AI-powered tools on the platform can assist users by summarizing lengthy documents, highlighting key items like equity plan changes, warrant issuances, and governance decisions, and helping readers understand how these regulatory filings relate to the company’s broader oncology strategy.
Citius Oncology, Inc. is conducting a primary offering of 1,284,404 shares of common stock at $1.09 per share to a single institutional investor, raising gross proceeds of about $1.4 million. After placement agent fees and expenses, the company expects net proceeds of approximately $1.04 million, which it plans to use to support the commercial launch of its FDA‑approved CTCL therapy LYMPHIR and for general working capital needs.
Concurrently, Citius Oncology is issuing in private placements pre‑funded warrants to purchase up to 15,229,358 shares of common stock and an equal number of common warrants, plus additional warrants to buy up to 1,284,404 shares, all outside this prospectus. Following the stock sale, common shares outstanding are expected to be about 84.8 million, assuming no exercise of the new or existing warrants.
Citius Oncology, Inc. reported results from its 2025 annual meeting. Stockholders approved an amendment to the 2024 Omnibus Stock Incentive Plan, increasing common shares authorized for issuance under the plan from 15,000,000 to 30,000,000 shares.
Votes on the plan amendment were 74,220,840 for, 106,247 against, 14,688 abstaining, and 3,462,017 broker non-votes. Class I directors Myron Holubiak (74,305,221 for; 36,554 withheld; 3,462,017 broker non-votes) and Joel Mayersohn (74,312,668 for; 29,107 withheld; 3,462,017 broker non-votes) were elected for terms expiring in 2028. Stockholders also ratified Wolf & Company, P.C. as independent auditor with 77,690,844 for, 36,459 against, and 76,489 abstaining.
Citius Oncology furnished an updated Corporate Presentation under Regulation FD. The company posted the presentation on October 23, 2025 and attached it as Exhibit 99.1 to a Form 8-K. The company states that the information in Item 7.01, including Exhibit 99.1, is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as specifically referenced.
Citius Oncology’s common stock trades on the Nasdaq Capital Market under the symbol CTOR.
Citius Oncology, Inc. (CTOR) is asking shareholders to elect two Class I directors, approve an amendment to its 2024 Omnibus Stock Incentive Plan to increase the share reserve from 15,000,000 to 30,000,000 shares, and to ratify Wolf & Company, P.C. as independent auditor for the fiscal year ending September 30, 2025. The proxy describes voting methods (internet, telephone, mail, or in person), procedures to revoke proxies, and vote thresholds: plurality for director elections and a majority of votes cast for the plan amendment and auditor ratification. The filing discloses director and officer names and ages, option awards and exercise terms (example: options exercisable at $2.15 expiring 07/05/2033), beneficial ownership data based on 83,513,442 shares outstanding as of September 10, 2025, and that certain directors and officers hold options exercisable within 60 days aggregating specific amounts (e.g., Mr. Mazur: 2,466,667 option shares). Compensation tables show selected salary and option grant values for 2023 and 2024 (examples: total reported for one executive was $661,875 in 2023 and $1,275,000 in 2024). The filing also lists committee responsibilities, nomination and shareholder proposal requirements, and corporate governance documents availability on the Company website.
Myron Z. Holubiak, a director and the company secretary of Citius Oncology, Inc. (CTOR), reported equity awards and option holdings. On 09/19/2025 he received 850,000 restricted shares that vest in three substantially equal installments on the first, second and third anniversaries of the grant, subject to continued service. The filing also reports 100,000 restricted shares granted the same day to his daughter, for which he disclaims beneficial ownership. Previously granted options include 300,000 options (exercise price $1.07) held directly and 50,000 options held indirectly by his daughter, both from a 12/12/2024 grant with 3-year vesting, plus 1,500,000 options (exercise price $2.15) from a 07/05/2023 grant that vest over three years.
Robert Joseph Smith, a director of Citius Oncology, Inc. (CTOR), reported equity awards and option holdings on Form 4. The filing shows a grant of 300,000 restricted shares on 09/19/2025 that vest in three substantially equal annual installments subject to continued service. The report also discloses ownership of 125,000 stock options granted 12/12/2024 with an exercise price of $1.07, exercisable in thirds on each anniversary and expiring 12/12/2034. After the reported restricted-stock grant, the filing lists 300,000 shares beneficially owned directly by the reporting person.
Leonard L. Mazur, Chief Executive Officer and Director of Citius Oncology, Inc. (CTOR), received equity awards on 09/19/2025 that materially change his beneficial ownership. The Form 4 reports a grant of 1,700,000 restricted shares that vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to continued service. The filing also shows outstanding stock options: 800,000 options with a $1.07 exercise price and 3,700,000 options with a $2.15 exercise price, each with multi-year vesting schedules. These awards reflect compensation through equity with time-based vesting conditions tied to continued service.
Citius Oncology director Carol Webb received equity compensation disclosed on Form 4. On 09/19/2025 she was granted 300,000 restricted shares that vest in three substantially equal installments on the first, second and third anniversaries of the grant, subject to continuous service. The filing also shows two stock option awards: 125,000 options with a $1.07 exercise price (granted 12/12/2024) and 150,000 options with a $2.15 exercise price (granted 07/05/2023). The 125,000 options vest over three years and the 150,000 options are fully vested. Ownership following the reported transactions is 300,000 shares directly beneficially owned.
Citius Oncology insider equity grants reported by Chief Medical Officer Myron Czuczman. The filing shows restricted stock awards of 825,000 shares granted on 09/19/2025 that vest in three substantially equal annual installments beginning one year after grant, subject to continued service. The reporting person also holds two stock option grants: 400,000 options with a $1.07 exercise price and a 12/12/2034 date shown, and 1,400,000 options with a $2.15 exercise price and a 07/05/2033 date; vesting schedules for the options are described in the filing. All holdings are reported as direct beneficial ownership.
Reporting person: Dennis M. McGrath, Director of Citius Oncology, Inc. (CTOR). Transaction: On 09/19/2025 Mr. McGrath was granted 300,000 restricted common shares at $0, which vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to continued service. He also holds two previously reported option grants: a $1.07 exercise-price option for 125,000 shares (granted 12/12/2024; vests one-third each year over three years) and a $2.15 exercise-price option for 150,000 shares (100% vested). Following the 09/19/2025 award, Mr. McGrath beneficially owns 300,000 shares directly plus the options described above. The Form 4 was signed by power of attorney on 09/23/2025.
FAQ
What is the current stock price of Citius Oncology (CTOR)?
What is the market cap of Citius Oncology (CTOR)?
